hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 12:58:32 - browse：859

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Complete sequence of Y chromosome published for first time

focus

WSS

Drug companies' payments and gifts affect physicians' prescribing

Bird flu reported in person exposed to presumably infected cattle

Republican states more likely to report Covid vaccine side effects

Neuroscience startup Neumora files for IPO

NYU Langone launches private ChatGPT for its health care data

Winners, losers from Medicare’s list of drugs subject to price talks

focus

hotspot

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

People with mental disorders often marry others with same

Psychedelics group wrestles with new pharma identity

Feds fine Medicare Advantage plans for overcharging members

Apple is now the first public company to be valued at $3 trillion

Radiation, mainstay of cancer treatment, begins a fade

State Dept. review finds Biden bears some blame for Afghanistan failures

Bird flu reported in person exposed to presumably infected cattle

Trump demands the U.S. pay no more for drugs than other countries … again

Insurer loopholes limit power of law against surprise medical bills

entertainment

Insurer loopholes limit power of law against surprise medical bills

Covid silver lining: Unprecedented look at human immune system

Four alarming medical procedures we’re glad history forgot

AstraZeneca bets AAV gene therapy will still deliver the goods

Neuroscience startup Neumora files for IPO

Scientific mystery highlights the blind spots in genomics databases

leisure time

focus

Wikipedia

knowledge